Dr. Aysun Ertaş
Check-ups & DiagnosticsVerified
- 23+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Imaging (MRI, CT, PET)
Gallium-68 dotatate pet-ct
What a gallium-68 DOTATATE PET-CT scan is, how the radiotracer binds to somatostatin receptors on neuroendocrine tumour cells, diagnostic accuracy compared with Octreoscan and FDG PET-CT, approximate costs in Turkey against the UK, US and Germany, scan preparation, what happens on the day, safety considerations and how to evaluate a nuclear medicine department.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Imaging (MRI, CT, PET)
- Hospitals
- 2
- Verified
- 2
- Price from
- Price on request
Verified surgeons for Gallium-68 DOTATATE PET-CT
2 doctors Compare doctors, ratings and prices — ask any of them for a free quote.
Uzm. Dr. Türkan Özer
Check-ups & DiagnosticsVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Gallium-68 DOTATATE PET-CT in Turkey: what it is and how it works
A gallium-68 dotatate pet-ct scan is a specialised molecular imaging procedure used to detect, stage, and monitor neuroendocrine tumours (NETs). The scan combines positron emission tomography (PET) with computed tomography (CT) using a targeted radiopharmaceutical called Gallium-68 DOTATATE. Neuroendocrine tumours frequently overexpress somatostatin receptors—particularly subtype 2 (SSTR2)—on their cell surfaces. The DOTATATE peptide binds selectively to these receptors, while the attached Gallium-68 radioisotope emits positrons detected by the PET camera. Simultaneous CT imaging provides cross-sectional anatomical detail, creating a fused three-dimensional map that pinpoints tumour locations with exceptional clarity.
Hospitals in Turkey use gallium-68 dotatate pet-ct scans for gastroenteropancreatic neuroendocrine tumours, bronchial carcinoids, pheochromocytomas, and paragangliomas, as well as to determine eligibility for peptide receptor radionuclide therapy (PRRT). This guide explains how the scan works, what clinical evidence shows, approximate costs in Turkey compared with the UK, US, and Germany, scan preparation, recovery, and how to verify clinic standards. For a broader overview of diagnostic imaging and screening packages, see our guide to checkup treatments in Turkey.
How does a gallium-68 DOTATATE PET-CT scan detect neuroendocrine tumours?
The diagnostic power of a gallium-68 dotatate pet-ct scan relies on receptor-targeted radiochemistry. The process begins with the synthesis of the tracer in a specialized radiopharmacy, where Gallium-68 (obtained from a generator or cyclotron) is chelated to DOTATATE. Once injected intravenously, the radiopharmaceutical circulates through the bloodstream and binds directly to somatostatin receptor subtype 2 (SSTR2) overexpressed on neuroendocrine tumour cells. Unbound tracer clears rapidly from circulation primarily through renal excretion.
Approximately 45 to 60 minutes after injection, the patient lies on the scanner bed. As the Gallium-68 isotope decays, it emits positrons that collide with local electrons, producing paired 511 keV gamma rays travelling in opposite directions. The PET detector rings record these coincident events to construct a map of metabolic tracer concentration. Simultaneously, the low-dose or diagnostic CT scanner captures structural cross-sections. Advanced software fuses the metabolic and anatomical datasets, enabling the nuclear medicine physician to measure the Standardized Uptake Value (SUVmax) of lesions and distinguish pathological tumour sites from physiological uptake in organs such as the spleen, kidneys, and pituitary gland.
Does gallium-68 DOTATATE PET-CT work and what does clinical evidence show?
Clinical evidence strongly validates the efficacy of gallium-68 dotatate pet-ct imaging. Major oncology and nuclear medicine societies, including the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the National Comprehensive Cancer Network (NCCN), recognise somatostatin receptor PET-CT as the diagnostic reference standard for well-differentiated neuroendocrine neoplasms. Prospective multicentre trials report diagnostic sensitivity between 92% and 96% and specificity between 90% and 95%, consistently outperforming older scintigraphic methods and standard contrast CT in detecting occult primary tumours and distant metastases.
In addition to initial staging, the scan plays a decisive role in theranostics. By confirming intense somatostatin receptor expression throughout metastatic lesions, it identifies patients who can benefit from targeted lutetium-177 (Lu-177) DOTATATE radionuclide therapy. However, the technique has clear biological boundaries. Poorly differentiated, high-grade neuroendocrine carcinomas (G3) often lose somatostatin receptor expression while increasing glucose metabolism; in such cases, fluorodeoxyglucose (18F-FDG) PET-CT provides more accurate staging. A trustworthy oncology team evaluates tumour grade and histology before recommending which molecular scan is appropriate.
Gallium-68 DOTATATE PET-CT cost in Turkey compared with the UK, US and Germany
The cost of a gallium-68 dotatate pet-ct scan reflects radiopharmaceutical production, cyclotron or generator maintenance, advanced imaging equipment, and specialist interpretation. In private European and American centres, pricing is often substantial due to radiotracer logistics and hospital overheads. The table below presents approximate cost ranges across countries based on private healthcare rates.
| Country | Approximate cost range |
|---|---|
| Turkey | €1,200 – €2,600 |
| United Kingdom | €2,800 – €5,500 |
| United States | €4,500 – €12,000 |
| Germany | €2,200 – €4,800 |
Several factors account for price variations: whether the CT component includes full-dose intravenous diagnostic contrast or low-dose attenuation correction, whether sedation is required, and whether pre-scan oncologist consultations are bundled into the booking. In Turkey, the gallium-68 dotatate pet-ct price generally covers tracer synthesis, the imaging procedure, nuclear medicine physician reporting, digital DICOM image storage on disc, and medical coordination. Patients can request a detailed clinical review and transparent price estimate via our free quote service before making travel arrangements.
Gallium-68 DOTATATE PET-CT vs Octreoscan, FDG PET-CT and MRI
Selecting the correct diagnostic imaging method depends on tumour biology, cellular differentiation, and clinical objectives. For decades, planar somatostatin receptor scintigraphy (Octreoscan using Indium-111) served as the standard nuclear test, but modern gallium-68 dotatate pet-ct imaging offers higher spatial resolution, detects lesions as small as 3 to 5 millimetres, and reduces procedure time from two days to under three hours.
| Imaging method | Best suited to | Typical limits |
|---|---|---|
| Gallium-68 DOTATATE PET-CT | Well-differentiated NETs (G1 and G2), staging, PRRT eligibility | Less sensitive for high-grade (G3) non-SSTR expressing tumours |
| Octreoscan (In-111 SPECT-CT) | Conventional somatostatin receptor scintigraphy when PET is unavailable | Lower spatial resolution, longer multi-day scanning protocol |
| 18F-FDG PET-CT | Aggressive, high-grade neuroendocrine carcinomas with high metabolic turnover | Misses low-grade, slow-growing NETs with normal glucose metabolism |
While specialized cancer diagnostics target specific molecular pathways, general oncological assessment often runs alongside broader screening modalities, such as diagnostic mammography or abdominal cross-sectional imaging. In complex neuroendocrine cases, oncologists sometimes combine gallium-68 DOTATATE with 18F-FDG PET-CT to evaluate tumour heterogeneity, identifying whether discordant, aggressive sub-clones exist within different metastatic sites.
Who needs a gallium-68 DOTATATE PET-CT scan and who is not suitable?
A gallium-68 dotatate pet-ct scan is indicated for patients with suspected or histologically confirmed neuroendocrine tumours. Typical candidates include individuals with gastroenteropancreatic neuroendocrine tumours (such as carcinoids, gastrinomas, insulinomas, and non-functioning pancreatic NETs), pulmonary carcinoids, and neural crest tumours including pheochromocytomas and paragangliomas. The scan is also recommended for locating an occult primary tumour when neuroendocrine metastases are discovered in the liver or lymph nodes, evaluating unexplained elevated chromogranin A levels, and monitoring treatment response after surgical resection or chemotherapy.
Conversely, the scan is not suitable for everyone. Patients with known high-grade, poorly differentiated small-cell or large-cell neuroendocrine carcinomas rarely benefit because their tumour cells lack sufficient SSTR2 density. Pregnant women should not undergo radionuclide imaging unless clinically unavoidable due to radiation exposure risks to the fetus. Breastfeeding mothers must temporarily interrupt nursing for approximately 12 hours after the injection to allow tracer clearance. Patients with severe renal impairment require careful assessment because delayed urinary excretion can elevate whole-body radiation exposure.
What happens during the scan appointment from preparation to injection?
Proper gallium-68 dotatate pet-ct preparation is vital for diagnostic accuracy. Patients receiving somatostatin analogue therapy (such as octreotide LAR or lanreotide) must coordinate with their oncologist: long-acting injections should be scheduled 3 to 4 weeks before the PET scan, or the scan should be performed just prior to the next scheduled dose to prevent medication from blocking receptor binding sites. Short-acting subcutaneous octreotide is typically discontinued 24 hours prior if clinically safe. Unlike standard FDG PET scans, strict fasting is not mandatory, but light meals and abundant water intake (1 litre) prior to arrival are advised to ensure optimal hydration.
On arrival at the nuclear medicine department, an intravenous cannula is inserted into your arm and the Gallium-68 DOTATATE tracer is administered. You then relax in a quiet uptake room for 45 to 60 minutes while the tracer circulates and binds to cellular receptors. Immediately before entering the scanner room, you will be asked to empty your bladder to clear radioactive urine from the pelvis. You then lie comfortably on the padded scanner couch while the table advances through the scanner bore. The scanning acquisition takes 20 to 30 minutes, during which you must remain still and breathe quietly. The entire hospital visit lasts approximately two to three hours.
Your trip to Turkey and gallium-68 DOTATATE PET-CT recovery
Arranging a gallium-68 dotatate pet-ct Turkey appointment generally requires a trip of two to three nights. Understanding how it works helps international patients coordinate travel, airport transfers, and local transport around their injection and scan timings. Day one is typically used for arrival, registration, and initial review of clinical notes. The scan is conducted on day two. On day three, the nuclear medicine specialist finalises the written evaluation, compares the scan with prior imaging, and provides the patient with a detailed report and digital imaging disc before travel home.
Because the procedure is non-invasive and performed without general anaesthesia, gallium-68 dotatate pet-ct recovery is immediate. You can eat your normal diet, resume walking, and return to everyday light activities straight after leaving the clinic. Drinking 1.5 to 2 litres of water throughout the remainder of the day accelerates the natural clearance of residual tracer through your kidneys. As a standard nuclear safety precaution, patients are advised to maintain a distance of one to two metres from young children and pregnant women for the first four to six hours following the injection, and to practice careful bathroom hygiene.
Gallium-68 DOTATATE PET-CT risks, radiation exposure and safety standards
Gallium-68 DOTATATE PET-CT is a well-established, low-risk diagnostic procedure. Established safety guidelines from the National Health Service (NHS), the European Association of Nuclear Medicine, and the U.S. Food and Drug Administration (FDA) indicate that the radiation exposure from the radiotracer is low, typically delivering an effective dose of 3 to 5 millisieverts (mSv). When combined with low-dose CT for attenuation correction and anatomical localisation, the total examination dose is approximately 4 to 8 mSv, which is comparable to one to three years of natural background radiation or a routine abdominal CT scan.
Adverse reactions to the DOTATATE peptide are exceedingly uncommon. Occasional mild and temporary symptoms reported in clinical monitoring include transient flushing, mild nausea, or slight irritation at the intravenous puncture site. If full diagnostic CT using iodinated contrast is performed simultaneously, the medical team checks renal function (creatinine and eGFR) and screens for iodine allergies beforehand. Regulated nuclear medicine centres adhere to strict ALARA (As Low As Reasonably Achievable) radiation protection principles to ensure patient safety.
How to choose an accredited nuclear medicine centre and questions to ask
When selecting a hospital for a gallium-68 dotatate pet-ct in Turkey, patients should verify that the nuclear medicine department possesses accredited radiopharmacy facilities and up-to-date PET-CT hardware, such as Time-of-Flight (TOF) detectors. Radiotracer quality control must adhere to strict international pharmacopeia standards because Gallium-68 has a half-life of only 68 minutes, requiring precise calibration and rapid administration. Furthermore, the interpreting physician should be a certified nuclear medicine specialist experienced in neuroendocrine tumour staging.
Red flags include clinics that cannot provide documented radiopharmacy protocols, facilities that do not inquire about your somatostatin analogue medication schedule, lack of an on-site nuclear medicine physician, or coordinators who cannot confirm that a comprehensive English-language report and DICOM image disc will be provided upon discharge. When communicating with the medical team, consider asking these practical questions:
- Is the imaging performed on a high-resolution Time-of-Flight PET-CT scanner?
- Does a certified nuclear medicine physician review the scans and author the final report?
- How should I adjust the timing of my somatostatin analogue injections before the scan?
- Does the quoted price include the Gallium-68 radiopharmaceutical, CT contrast, and reporting fees?
- Will I receive a digital copy of the complete DICOM scan files and an English report before returning home?
- What specific radiation safety measures should I follow regarding travel and contact with others?
You can learn more about how it works before travelling abroad for nuclear imaging. Before committing to travel, patients can also review other specialised modalities under checkup treatments in Turkey and submit their clinical records for a free quote.
Hospitals with Check-ups & Diagnostics in Turkey
Frequently asked questions
A gallium-68 DOTATATE PET-CT scan is a specialised molecular imaging technique used primarily to detect, stage, and monitor neuroendocrine tumours. A targeted radiopharmaceutical, gallium-68 DOTATATE, is injected into the bloodstream, where it binds to somatostatin receptors on tumour cells. The combined PET and CT scanner detects this radiotracer, providing precise three-dimensional maps of tumour locations.
Yes, extensive clinical studies demonstrate that it provides high diagnostic accuracy for well-differentiated neuroendocrine tumours, with sensitivity and specificity frequently exceeding ninety percent. It identifies primary lesions, lymph node involvement, and distant bone or liver metastases earlier and more clearly than conventional cross-sectional imaging, helping oncologists select appropriate surgical or peptide receptor radionuclide therapies.
In Turkey, a gallium-68 DOTATATE PET-CT scan typically ranges from €1,200 to €2,600, compared with €2,800 to €5,500 in the UK and higher in the US. The total cost depends on hospital facilities, whether diagnostic contrast CT is performed concurrently, and whether specialist nuclear medicine consultations and translation services are included.
Serial PET-CT scans compare tumour receptor avidity and tumour volume before and after treatments such as surgery, chemotherapy, or PRRT. A reduction in radiotracer uptake or lesion size indicates a positive therapeutic response, whereas new areas of uptake or rising intensity suggest disease progression, enabling clinicians to tailor treatment plans.
Gallium-68 DOTATATE PET-CT has largely superseded traditional Indium-111 Octreoscan in modern oncology. PET-CT offers markedly higher spatial resolution, allowing detection of sub-centimetre lesions missed by SPECT. Furthermore, the Gallium-68 procedure requires only a single two-hour visit with lower patient radiation exposure, whereas Octreoscan requires multiple imaging sessions over twenty-four to forty-eight hours.
The scan itself causes no physical sensation, as the scanner does not touch your body. The only mild discomfort is the brief needle insertion for the intravenous injection in your arm, similar to a standard blood test. During image acquisition, you simply lie still on a padded examination couch.
The entire clinical visit usually takes between two and three hours. After registration and medical review, the radiotracer is administered intravenously, followed by a sixty-minute resting period in a quiet room to allow cellular uptake. The actual scan inside the PET-CT machine takes twenty to thirty minutes, followed by a brief observation.
Recovery is immediate with no sedation required. Patients can resume normal eating, light activities, and work immediately after leaving the clinic. Drinking abundant fluids throughout the day accelerates the natural urinary clearance of the tracer. Basic radiation safety precautions, such as avoiding prolonged close contact with infants or pregnant women, apply for several hours.
Yes, the radiation dose is low and considered safe under clinical supervision. The effective dose is typically between three and five millisieverts, comparable to one to two years of natural background radiation or a routine abdominal CT. Side effects or allergic reactions to the DOTATATE peptide tracer are exceedingly rare.
Most international patients stay in Turkey for two to three days. This schedule allows sufficient time for initial consultation, scan preparation, image acquisition, and waiting for the nuclear medicine physician to generate a comprehensive written report and digital disc before your flight home.
Patient stories